Helius Medical Technologies, Inc. to Participate in Noble Capital Markets’ Virtual Road Show Series

Rhea-AI Summary

Helius Medical Technologies, a neurotech company, will participate in Noble Capital Markets’ Virtual Road Show Series on June 10, 2021. The event will feature a corporate presentation followed by a Q&A session led by Senior Research Analyst Joe Gomes. Interested parties can register for the live webcast at 1:00 p.m. Eastern Time, and a recording will be available afterwards. Helius is focused on developing non-invasive technologies that enhance neurological wellness, including the Portable Neuromodulation Stimulator (PoNS), aimed at treating gait deficits from conditions like multiple sclerosis.

NEWTOWN, Pa., June 08, 2021 (GLOBE NEWSWIRE) -- Helius Medical Technologies, Inc. (Nasdaq:HSDT) (TSX:HSM), (“Helius” or the “Company”), a neurotech company focused on neurological wellness, today announced its participation in Noble Capital Markets’ Virtual Road Show Series, presented by Channelchek, which is scheduled for Thursday, June 10, 2021.

The event will feature a corporate presentation followed by a Q&A session proctored by Noble Capital Markets’ Senior Research Analyst, Joe Gomes, featuring questions submitted by the audience.

The live webcast of the event is scheduled for June 10, 2021, at 1:00 p.m. Eastern. Register for the webcast here. A recording will be available on Channelchek and under the ‘Events’ section of the Helius Medical Technologies investor relations website at https://heliusmedical.com/index.php/investor-relations/events/upcoming-events.

About Helius Medical Technologies, Inc.

Helius Medical Technologies is a neurotech company focused on neurological wellness. The Company’s purpose is to develop, license and acquire unique and non-invasive platform technologies that amplify the brain’s ability to heal itself. The Company’s first commercial product is the Portable Neuromodulation Stimulator (PoNS^TM). For more information, visit www.heliusmedical.com.

About the PoNS^TM Device and PoNS Treatment^TM

The Portable Neuromodulation Stimulator (PoNS^TM) is an innovative non-surgical device, inclusive of a controller and mouthpiece, which delivers electrical stimulation to the surface of the tongue to provide treatment of gait deficit. The PoNS device is indicated for use in the United States as a short term treatment of gait deficit due to mild-to-moderate symptoms from multiple sclerosis (“MS”) and is to be used as an adjunct to a supervised therapeutic exercise program in patients 22 years of age and over by prescription only. It is authorized for sale in Canada as a class II, non-implantable, medical device intended as a short term treatment (14 weeks) of gait deficit due to mild and moderate symptoms from MS, and chronic balance deficit due to mild-to-moderate traumatic brain injury (“mmTBI”) and is to be used in conjunction with physical therapy. The PoNS^TM is an investigational medical device in the European Union (“EU”) and Australia (“AUS”). It is currently under premarket review by the AUS Therapeutic Goods Administration.

Investor Relations Contact:

Westwicke Partners on behalf of Helius Medical Technologies, Inc.
Jack Powell, Vice President
investorrelations@heliusmedical.com

FAQ

What date is HSDT participating in the Noble Capital Markets’ Virtual Road Show?

Helius Medical Technologies (HSDT) will participate on June 10, 2021.

What is the purpose of HSDT's presentation in the Virtual Road Show?

The presentation will showcase Helius's corporate information followed by a Q&A session.

What time does the HSDT webcast start during the Virtual Road Show?

The webcast is scheduled to start at 1:00 p.m. Eastern Time.

Where can I register for HSDT's Virtual Road Show webcast?

You can register for the webcast on Noble Capital Markets' or Helius Medical Technologies' investor relations website.

What is the Portable Neuromodulation Stimulator (PoNS) device?

The PoNS device is a non-surgical treatment for gait deficits associated with multiple sclerosis.